Roth Comments on Ligand (LGND) Following Approval of Promact sNDA (GSK)
Tweet Send to a Friend
Roth Capital affirms Ligand Pharma (Nasdaq: LGND) at Buy with a target price of $92 following an announcement that GlaxoSmithSline ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
